UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 28, 2007

BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)

 
					
Delaware	 	1-1136	 	22-079-0350	
(State or Other Jurisdiction
of Incorporation)	 	(Commission File Number)	 	(IRS Employer
Identification Number)	
345 Park Avenue
New York, NY, 10154
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

 
Item 8.01.	Other Events.	
On September 28, 2007, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing that it has finalized a civil settlement agreement with the United States Department of Justice (“DOJ”) and the Office of the United States Attorney for the District of Massachusetts resolving the previously disclosed investigations that began several years ago involving the Company’s drug pricing, and sales and marketing activities. In connection with the settlement, the Company has entered into a five-year corporate integrity agreement with the Office of the Inspector General of the Department of Health and Human Services (“OIG”) that provides for, among other obligations, the continued development and maintenance of the Company’s compliance programs relating to the Company’s U.S. pharmaceuticals business.
As previously announced, the agreement provides for a civil resolution and payment of $499 million the full amount of which has been reserved. There are no criminal charges against the Company. The agreement will not affect the Company’s ongoing business with any customers, including the government.
A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01.	Financial Statements and Exhibits.	
(d) Exhibits.
 
 	99.1	Press release of Bristol-Myers Squibb Company dated September 28, 2007	

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	 	 	 	BRISTOL-MYERS SQUIBB COMPANY	
				
Dated: September 28, 2007	 		 	By:	 	/s/ Sandra Leung	
	 		 	Name:	 	Sandra Leung	
	 		 	Title:	 	Senior Vice President and General Counsel	

EXHIBIT INDEX

Exhibit No.	 	Description	
99.1	 	Press release of Bristol-Myers Squibb Company dated September 28, 2007	
  
Exhibit 99.1

					
Contact:	  	Media:	  	Investors:	
	  	Jeff Macdonald	  	John Elicker	
	  	Communications	  	Investor Relations	
	  	212-546-4824	  	212-546-3775	
	  	jeffrey.macdonald@bms.com	  		
			
	  	Laura Hortas	  		
	  	Communications	  		
	  	609-252-4587	  		
	  	laura.hortas@bms.com	  		
BRISTOL-MYERS SQUIBB FINALIZES SETTLEMENT OF PREVIOUSLY
DISCLOSED FEDERAL
INVESTIGATION INTO PRICING, SALES AND MARKETING PRACTICES
NEW YORK (September 28, 2007)—Bristol-Myers Squibb Company announced today that it has finalized a civil settlement agreement with the United States Department of Justice (“DOJ”) and the Office of the United States Attorney for the District of Massachusetts resolving the previously disclosed investigations that began several years ago involving the company’s drug pricing, and sales and marketing activities. The company announced in December 2006 that an agreement in principle had been reached. In connection with the settlement, the company has entered into a five-year corporate integrity agreement with the Office of the Inspector General of the Department of Health and Human Services (“OIG”) that provides for, among other obligations, the continued development and maintenance of the company’s compliance programs relating to the company’s U.S. pharmaceuticals business.
As previously announced, the agreement provides for a civil resolution and payment of $499 million, the full amount of which has been reserved. There are no criminal charges against the company. The agreement will not affect the company’s ongoing business with any customers, including the government.

Bristol-Myers Squibb is pleased to have resolved these matters from the past and is proud of its commitment to conduct business with the highest standards of integrity in its mission to extend and enhance human life.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
###